SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Lithium Americas Corp. engages in the development of the Thacker Pass project. It is focused on advancing Thacker Pass to production it is located in northern Nevada. The company was founded on January 23, 2023 and is headquartered in Vancouver, Canada.

Lithium Americas Corp (NewCo)

Lithium Americas Corp

Lithium Americas ($LAC) is trending amid speculation that the U.S. government may take a stake in the company, potentially restructuring a significant loan for its Thacker Pass project. The community is actively discussing the implications of government involvement and potential partnerships with companies like Tesla and GM, with many anticipating a sustained upward trend. The stock is seeing monster volume as traders debate whether the stock will break up or down.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a surge in investor interest, fueled by a recent Air Force contract and non-dilutive funding, which validates the company's quantum computing roadmap. The community is actively discussing the stock's potential, comparing it to other high-growth tech stocks and debating whether it's overvalued. Some traders are pointing to a potential short squeeze, while others highlight the long-term potential of quantum computing and the company's partnerships.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Despite positive sentiment around potential rate cuts benefiting Upstart, the stock is trending due to a recent pullback, leading to community discussions about support levels and potential bottom fishing. Some traders are expressing frustration with the stock's performance compared to others in the fintech sector, while others are anticipating a short squeeze. Overall, the conversation revolves around whether the current dip presents a buying opportunity or signals further downside.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending due to positive data from its Huntington's disease gene therapy trial, with analysts raising price targets. The community is weighing the potential for accelerated FDA approval and a possible buyout, while some caution about a potential offering given the stock's surge.

Astera Labs, Inc. is a global semiconductor company, which engages in the provision of hardware and software solutions for AI and cloud infrastructure applications to solve data, memory, and networking bottlenecks. It operates through the following geographical segments: Taiwan, China, United States, and Other. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

ALAB is trending due to a significant sell-off, with community members citing potential Intel/Nvidia competition and overvaluation concerns as possible catalysts; some suspect market manipulation. Despite strong YTD growth fueled by PCIe demand and a recent positive earnings report, investors are debating its sustainability amid competition from major players like AVGO and MRVL. Discussions include whether the drop is a buying opportunity or a sign of further declines.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending with community members actively discussing its recent price surge and potential for further gains, while others debate its valuation and potential risks. Bullish sentiment seems to be fueled by Elon Musk's recent activity and anticipation of future developments, contrasting with bearish concerns about market conditions and the company's fundamentals. The stock's price action is prompting speculation about a possible short squeeze and a test of all-time highs.

Freeport-McMoRan, Inc. engages in the mining of copper, gold, and molybdenum. It operates through the following segments: North America Copper Mines, South America Operations, Indonesia Operations, Molybdenum Mines, Rod and Refining, Atlantic Copper Smelting and Refining, and Corporate and Other. The North America Copper Mines segment operates open-pit copper mines in Morenci, Bagdad, Safford, Sierrita, Miami in Arizona and Chino, and Tyrone in New Mexico. The South America Operations segment includes Cerro Verde in Peru and El Abra in Chile. The Indonesia Operations segment handles the operations of the Grasberg minerals district that produce copper concentrate containing significant quantities of gold and silver. The Molybdenum Mines segment includes the Henderson underground mine and Climax open pit mine, both in Colorado. The Rod and Refining segment consists of copper conversion facilities located in North America and includes a refinery and rod mills. The Atlantic Copper Smelting and Refining segment smelts and refines copper concentrate and markets refined copper and precious metals in slimes. The Corporate and Other segment offers other mining and eliminations, oil and gas operations, and other corporate and elimination items. The company was founded by James R. Moffett on November 10, 1987, and is headquartered in Phoenix, AZ.

Freeport-McMoRan Inc

Freeport-McMoRan is trending due to a deadly mudslide at its Grasberg mine in Indonesia, leading to halted operations and lowered copper/gold sales estimates, causing a stock decline. The community is focused on the production impacts and the potential for supply disruptions to boost copper prices, while some express concerns over the long-term financial implications and safety risks in mining. Broader discussion includes the potential effect on global commodity markets.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is trending as investors anticipate upcoming data releases, particularly from the open-label extension study. The community is buzzing about the potential for positive results to drive the stock higher, with some drawing comparisons to other successful biotech companies. Bullish sentiment is fueled by analyst ratings and a belief that the company is undervalued given its cash position and potential to address a rare disease.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in Alpharetta, GA.

Bakkt Holdings Inc - Ordinary Shares - Class A

Bakkt Holdings Inc

BKKT is trending as the community discusses the potential impact of a new board member with a strong track record, particularly his past success with IREN.  Bullish sentiment is fueled by speculation about future strategic moves and potential partnerships, especially with SoftBank, driving significant interest in call options.  However, some traders remain skeptical, citing the stock's history and volatility.

TNF Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

TNF Pharmaceuticals Inc.

TNF Pharmaceuticals (TNFA) is trending as traders discuss its recent strategic shift towards quantum computing and a name change to Q/C Technologies, sparking both excitement and skepticism. Bullish sentiment centers on the potential of their exclusive rights to light-speed laser processing for cryptocurrency applications, while bears cite concerns about dilution and the company's history. The community is actively debating whether this pivot justifies the stock's increased volatility and potential for a short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TNF Pharmaceuticals, Inc. (TNFA) announced on Wednesday that it has changed its corporate name to Q/C Technologies and will begin trading under a new ticker on the Nasdaq Capital Market starting Thursday.TNF Pharmaceuticals stated that no action is required from current shareholders regarding the name change. The firm <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tnfpharma.com/news-events/press-releases/detail/81/tnf-pharmaceuticals-announces-name-change-to-qc">noted</a> that the new name represents the company’s recent strategic pivot into quantum-class computing. The company has exclusive global rights to LightSolver’s light-speed laser processing unit (LPU), a light and laser-based computing system for application in the cryptocurrency vertical.LPUs can reduce energy consumption by up to 90% while outperforming traditional GPUs and quantum computing in both speed and efficiency, the company said. Lighsolver’s architecture is further designed to improve security for blockchain operations and is expected to position the company at the forefront of innovation in blockchain infrastructure, the company said.Following the announcement, <a href="https://stocktwits.com/symbol/TNFA">TNFA shares</a> surged by about 101% by the afternoon of Wednesday. On Stocktwits, retail sentiment around TNFA jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘high’ levels. The stock will begin trading under the new ticker symbol QCLS starting Thursday, September 25.The company added that it also continues to evaluate strategic options for its therapeutic programs, Isomyosamine and Supera-CBD. While Isomyosamine has potential for the treatment of chronic inflammation, Supera-CBD holds potential in managing addiction. The company is looking to realize maximum value from these assets as it undertakes the pivot into computing and blockchain infrastructure.TNFA stock is down by 94% this year.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/harmony-biosciences-stock-slumps-after-rare-genetic-disorder-drug-fails-late-stage-study/chD1BhBR3Ed">Harmony Biosciences Stock Slumps After Rare Genetic Disorder Drug Fails Late-Stage Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

TNF Pharmaceuticals Stock More Than Doubles After Announcing Name Change To Represent Pivot Into Quantum-Class Computing

The company holds exclusive global rights to LightSolver’s light-speed laser processing unit (LPU), a light and laser-based computing system designed for use in the cryptocurrency sector.

TNF Pharmaceuticals Stock Nearly Doubles After Announcing Name Change To Represent Pivot Into Quantum-Class Computing

Equity

The company holds exclusive global rights to LightSolver’s light-speed laser processing unit (LPU), a light and laser-based computing system designed for use in the cryptocurrency sector.


Retail chatter spiked last week as investors piled into three healthcare stocks: GlucoTrack, Sarepta Therapeutics, and TNF Pharmaceuticals, which recorded the highest increases in message volume among healthcare names on Stocktwits.GlucoTrack (GCTK)GlucoTrack posted the highest increase in retail chatter, with message volume surging 3,700% over the past seven days. As of late Sunday, sentiment remained ‘bullish’ among retail traders.On July 8, the company announced the repurchase of over 90% of its Series A Warrants, funded with cash on hand.&nbsp;The move followed last month’s disclosure of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/glucotrack-announces-positive-results-from-implantable-blood-glucose-monitor-study/chmJoJwRREo">positive results</a> from its first-in-human clinical study of its continuous blood glucose monitor (CBGM).The implantable device demonstrated 99% data capture, strong accuracy, and no serious adverse events. Designed for a three-year lifespan, the CBGM measures blood glucose directly, not interstitial fluid, and requires no on-body wearable.&nbsp;A long-term feasibility study is expected to launch in Q3 2025.<a href="https://stocktwits.com/symbol/GCTK">GCTK’s stock</a> has declined 98.5% so far in 2025.Sarepta Therapeutics (SRPT)Sarepta saw a 1,991% increase in message volume over the past week, with sentiment remaining ‘extremely bullish’ as of late Sunday, despite mounting regulatory concerns.On July 19, shares plunged over 26% in midday trading after FDA Commissioner Marty Makary said the agency is&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fda-taking-a-hard-look-to-at-whether-sarepta-gene-therapy-elevidys-should-remain-on-the-market/ch8kDByR5qt">“taking a hard look”</a> at whether Sarepta’s gene therapy, Elevidys, should stay on the market.The company disclosed a third patient death on July 18, involving a 51-year-old participant in a limb-girdle muscular dystrophy trial using a similar viral vector to Elevidys. Two earlier deaths were already under FDA investigation. Reuters reported the agency plans to request a voluntary halt to Elevidys' shipments.Amid the fallout,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-draws-wall-street-ire-after-third-patient-death-this-year/ch8kMF7R5qY">analysts criticized Sarepta</a> for not disclosing the fatality earlier, particularly during a recent business update where it announced a 500-job layoff and $400 million in cost cuts.&nbsp;The company has since paused shipments to non-ambulatory patients and&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-surges-after-hours-as-it-slashes-500-jobs-amid-fda-black-box-warning-for-gene-therapy-retail-eyes-rebound/ch8KR0HR5oM">agreed to a black box warning</a> for Elevidys, citing the risk of acute liver failure.<a href="https://stocktwits.com/symbol/SRPT">SRPT’s stock</a> has declined 88.7% so far in 2025.TNF Pharmaceuticals (TNFA)TNF Pharma recorded a 1,900% rise in message volume over the past seven days on Stocktwits, with sentiment labeled ‘extremely bullish’ as of late Sunday.Although there was no specific news catalyst driving the buzz last week, the momentum has been strong since last month when TNFA announced a Compassionate Use collaboration with the DADA2 Foundation to study isomyosamine as a treatment for DADA2, a rare pediatric autoinflammatory disorder.In April,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tnf-pharmaceuticals-to-use-ai-to-recruit-patients/chQSz8ARbXp">TNFA partnered with Renova Health</a> to apply AI and machine learning to optimize patient recruitment. The company is analyzing data from 30,000 patients to identify high-risk cohorts, particularly for interventions related to inflammation and side effects of GLP-1 therapy.TNFA’s pipeline includes two drug platforms: isomyosamine, which regulates inflammatory pathways, and Supera-CBD, which targets chronic pain, addiction, and epilepsy.<a href="https://stocktwits.com/symbol/TNFA">TNFA’s stock</a> has declined 92.4% so far in 2025.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amazon-stealthily-hiked-prices-on-everyday-essentials-as-trump-tariffs-bit-report/ch8qvlTR5Ae">Amazon Stealthily Hiked Prices On Everyday Essentials As Trump Tariffs Bit: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

GlucoTrack (GCTK), Sarepta Therapeutics (SRPT), and TNF Pharmaceuticals (TNFA) recorded the highest increases in message volume among healthcare names on Stocktwits. (Photo credit: Getty Images)

GlucoTrack, Sarepta, TNF Pharma Dominate Weekly Retail Health Care Buzz — Here’s Why

GlucoTrack repurchased over 90% of its Series A warrants, while Sarepta disclosed a third patient death, suspended Elevidys shipments, and added a black-box warning amid FDA scrutiny.

Shares of TNF Pharmaceuticals, Inc. (TNFA) traded nearly 5% higher on Tuesday afternoon after it announced a partnership with Renova Health for the application of AI and machine learning technologies to recruit patients for its isomyosamine drug development.Isomyosamine is a drug platform based on a clinical stage small molecule that is being developed to treat diseases and disorders marked by acute or chronic inflammation.The clinical-stage pharmaceutical company stated that it would use Renova Health’s proprietary AI and machine learning technology to identify high-risk patient groups that may benefit the most from interventions that preserve lean muscle mass during GLP-1 treatment for diabetes, weight loss, and chronic weight management.The company stated that the TNF-Renova partnership is analyzing data from 30,000 patients to identify high-risk patients.Renova CEO David Jacobs said that its technology transcends traditional big data analytics by creating highly specific patient personas.“Our platform uncovers the nuanced impact of individual physician practices—such as varying diagnosis codes for GLP-1 prescriptions, like BMI versus diabetes—which can significantly influence cohort selection and study outcomes,” he said.Isomyosamine is the first of two therapeutic platforms being developed by TNF Pharmaceuticals. While Isomyosamine is being developed to regulate inflammation, the company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy.On Stocktwits, retail sentiment around TNF remained unmoved in the ‘bearish’ territory over the past 24 hours while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:1292/304;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_22_at_2_09_23_PM_png_87841bd4ef.webp" alt="TNFA's Sentiment Meter and Message Volume as of 2:05 p.m. ET on April 22, 2025 | Source: Stocktwits" width="1292" height="304"><figcaption>TNFA's Sentiment Meter and Message Volume as of 2:05 p.m. ET on April 22, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/TNFA">TNFA stock</a> is down by over 84% so far this year and by over 93% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/jd-vance-says-significant-progress-made-with-india-on-trade-deal/chQSwMaRbXn">Vice President JD Vance Calls Indian PM Narendra Modi A ‘Tough Negotiator’ As US, India Negotiate Bilateral Trade Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

TNF Pharmaceuticals To Use AI To Recruit Patients For Drug Development: Retail Stays Bearish

The company said that it would use Renova Health’s proprietary AI and machine learning technology to identify high-risk patient groups that may benefit the most from interventions that preserve lean muscle mass during GLP-1 treatment.

The company said that it would use Renova Health’s proprietary AI and machine learning technology to identify high-risk patient groups that may benefit the most from interventions that preserve lean muscle mass during GLP-1 treatment for diabetes, weight loss, and chronic weight management.

TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (TNF or the Company), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today...

TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (TNFA or the Company), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions...

TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs

TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference

TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market

TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (TNFA or the Company), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and...

Will Costco Wholesale ($COST) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

Stocktwits

Costco Wholesale Corp

) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

TNFA
TNF Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TNFA News

TNFA TNF Pharmaceuticals Inc.